Erudio Healtherudio.com
Clinical trial · no report yet · Phase 2/Phase 3
BR.36
Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
- NCT04093167 ↗
- Active, not recruiting
- Canadian Cancer Trials Group
- Deep
We haven't built an HCP commentary report on BR.36 (pembrolizumab plus platinum-based chemotherapy in non-small cell lung cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on BR.36 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| X threads | 21 | |
| Podcasts | 5 | |
| YouTube | 1 |
The trial
ClinicalTrials.gov- Official title
- A Biomarker-Directed, Multi-Centre Phase II/III Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer
- Phase
- Phase 2/Phase 3
- Status
- Active, not recruiting
- Conditions
- Lung Cancer
- Interventions
- Pembrolizumab
- Arms
- Pembrolizumab alone · Active comparator
- Pembrolizumab + standard platinum-based chemotherapy · Experimental
- Enrollment
- 53
- Primary outcomes
- Stage 1: Concordance rate between molecular response and radiologic response
- Stage 2: Phase II Progression-Free Survival (PFS)
- Stage 2: Phase III Overall Survival
- Sponsor
- Canadian Cancer Trials Group with Cancer Research Institute, New York City, Personal Genome Diagnostics, Mark Foundation for Cancer Research
- Start
- May 26, 2020
- Primary completion
- Dec 31, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT04093167 · updated Jul 31, 2026
Publications
linked from the registry- Anagnostou V, Ho C, Nicholas G, Juergens RA, Sacher A, Fung AS, Wheatley-Price P, Laurie SA, Levy B, Brahmer JR, Balan A, Niknafs N, Avrutin E, Zhu L, Sausen M, Bradbury PA, O'Donnell-Tormey J, Gaudreau PO, Ding K, Dancey J. ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results. Nat Med. 2023 Oct;29(10):2559-2569. doi: 10.1038/s41591-023-02598-9. Epub 2023 Oct 9. PubMed 37814061